Arterra Bioscience (ARBS) Q4 2025 TU earnings summary

Executive summary

• Revenue for the year ended December 31, 2025, reached €4.6 million, up 11.42% year-over-year.

• Growth attributed primarily to increased sales of cosmetic raw materials, which rose 12.62% compared to the previous year.

• Achieved targets align with management's expectations, with a positive outlook for early 2026.

Financial highlights

• Total revenue increased from €4.17 million in 2024 to €4.65 million in 2025.

• Service revenue grew by 4.94% year-over-year, from €653.76k to €686.05k.

• Cosmetic raw material sales rose from €3.52 million to €3.96 million, a 12.62% increase.

Outlook and guidance

• Management expresses optimism for 2026 based on initial data and ongoing commercial development.